How adult drugs from the group of MAP kinase inhibitors can also be used in children with cancer in a standardized manner worldwide has now been outlined in a statement in the renowned European Journal of Cancer.
The authors of this review are stakeholders from all relevant fields. A major goal of the initiative is to test the most effective and tolerable MAP kinase inhibitor in clinical trials, thus enabling rapid market approval and availability for children.
Comments
Thank you. Comment sent for approval.
Something is wrong, try again later